Karat Packaging Launches Initial Public Offering
04/07/2021 | 12:43pm EDT
Send by mail :
Message :
Required fields
CHINO, Calif., April 07, 2021 (GLOBE NEWSWIRE) Karat Packaging Inc. (“Karat Packaging” or the “Company”), a specialty distributor and manufacturer of environmentally-friendly disposable foodservice products and related items, today announced it has launched the roadshow for the initial public offering of 3,950,000 shares of its common stock. The Company also has granted the underwriters a 30-day option to purchase up to an additional 592,000 shares of common stock, on the same terms and conditions, to cover over-allotments, if any. The offering price is expected to be between $18.00 and $20.00 per share. Karat Packaging has applied to list its common stock on The Nasdaq Global Market under the ticker symbol “KRT.”
Summer Street Capital Partners Announces Sale of Curtis Bay Medical Waste Services
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Summer Street Capital Partners Announces Sale of Curtis Bay Medical Waste Services
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise .
ProQR Therapeutics N.V.April 5, 2021 GMT
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the underwriters’ option to purchase up to 2,076,923 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled approximately $103.5 million, before deducting underwriting discounts and
Share this article
Share this article
SEATTLE, March 31, 2021 /PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC) ( CTI ), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X
1 preferred stock (the Series X
1 Preferred ). In addition, CTI has granted the underwriters a 30-day option to purchase up to an additional 2,139,120 shares of its common stock on the same terms and conditions. The offering price to the public of a share of common stock is $2.50 and the offering price to the public of a share of Series X